Terumo BCT
Terumo BCT is the blood and cell technology division of Terumo Corporation, providing automated blood collection and processing systems, therapeutic apheresis platforms (Spectra Optia, 84% global market share), and cell therapy manufacturing systems (Quantum Flex, FINIA) to blood centers, hospitals, plasma collectors, and cell and gene therapy developers across 160+ countries.
- Company typePrivate
- Founded1964
- HeadquartersLakewood, United States
- Headcount5,001–10,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Terumo BCT does
Terumo Blood and Cell Technologies (Terumo BCT) is the dedicated blood and cell technology division of Terumo Corporation (TSE: 4543), founded in 1964 and headquartered in Lakewood, Colorado, with operations in 160+ countries supported by 5 regional headquarters, 28+ sales offices, 8 manufacturing sites, and 7 innovation and development centers. The company develops medical technology for the collection, processing, and therapeutic delivery of blood and cell-based treatments, organized into three product franchises: Global Blood Solutions (Trima Accel blood collection, Reveos automated whole-blood processing, Mirasol pathogen reduction, IMUGARD platelet pooling, whole-blood bag systems), Therapeutic Apheresis (Spectra Optia, which performs 84% of blood cell separation and exchange procedures worldwide, plus EMPOWERD data management), and Cell Therapy Technologies (Quantum Flex hollow-fiber bioreactor for automated cell expansion, FINIA fill and finish). The platform is protected by 750+ granted patents and 150+ pending applications, and integrates with partner technologies from Nova Biomedical, FUJIFILM Irvine Scientific, 908 Devices, MCQ, Charles River, and StafaCT.
Terumo BCT sells capital equipment (apheresis systems, blood processors, cell expansion bioreactors) via direct enterprise field sales through regional headquarters covering the Americas, EMEA, Asia, and ANZ, with quote-based pricing and recurring revenue from proprietary consumables (blood bag systems, platelet pooling sets, single-use kits), software licenses (TOMEs, Cadence, Vista, EMPOWERD, Trima KPI Dashboard), and service contracts including Veda Solutions analytics and consulting. The customer base spans blood and plasma collection centers (CSL Plasma, SunCoast, Sanquin, Carter BloodCare, Blood Centers of America), hospitals and therapeutic apheresis clinics (UK NHS, University of Chicago, Anthony Nolan), and cell and gene therapy developers (Taiwan Bio Therapeutics, Steminent, Akron Bio, BioCentriq, CiRA Foundation).
Revenue is generated from a mix of one-time capital hardware sales, recurring consumables tied to installed base, subscription-style software and data services, and contract manufacturing; pricing is quote-based and contract terms are typically multi-year. The company is currently pursuing aggressive geographic expansion (Africa HQ, China localization), C> ecosystem buildout (APAC C> Ecosystem Blueprint, multiple developer partnerships), and growth into new therapeutic areas (sickle cell disease via the Imara Framework, sepsis via Santersus collaboration), supported by Terumo Ventures investments in adjacent technologies.
Terumo BCT firmographics
Firmographics- Name
- Terumo BCT
- Legal name
- Terumo BCT, Inc.
- Website
- https://terumobct.com
- Company type
- Private
- Founded year
- 1964
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Terumo BCT is the blood and cell technology division of Terumo Corporation, providing automated blood collection and processing systems, therapeutic apheresis platforms (Spectra Optia, 84% global market share), and cell therapy manufacturing systems (Quantum Flex, FINIA) to blood centers, hospitals, plasma collectors, and cell and gene therapy developers across 160+ countries.
- Ownership category
- akta.pro rank
Terumo BCT industry classification
Industry- Product category
- Blood and Cell Processing Medical Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical Equipment and Supplies Manufacturing (33911)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Cell Therapy CDMO (HLAGABAD)
- akta.pro secondary industry
- Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN)
Keywords
Where Terumo BCT is headquartered
LocationHeadquarters
- HQ city
- Lakewood
- HQ country
- United States
- HQ region
- North America
Offices29 records
Markets served
Terumo BCT business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure
Revenue model
- Medical Device Hardware Sales: Sale of medical devices and systems including apheresis machines, blood processing systems, cell expansion bioreactors, and related equipment. One-time capital equipment sales with consumables revenue from blood bag systems, accessories, and single-use components.
- Software and Services: Software solutions including TOMEs, Vista Information System, Cadence Data Collection System, Trima KPI Dashboard, and Veda Solutions for analytics and consulting. Ongoing software licenses and service contracts.
- Contract Manufacturing: Contract manufacturing services for medical devices and blood/cell processing products.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Enterprise medical device pricing - quote-based for capital equipment |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels8 records
Terumo BCT product offering
Product offeringCore offering
Terumo BCT develops, manufactures, and services medical technology products for the collection, processing, and delivery of blood and cell-based therapies. The portfolio spans automated blood collection and processing systems (Trima Accel, Reveos), therapeutic apheresis platforms (Spectra Optia), cell therapy manufacturing systems (Quantum Flex, FINIA), pathogen reduction technology (Mirasol), plasma collection systems (Rika), and supporting consumables and data management software.
Product overview
Terumo Blood and Cell Technologies offers an integrated portfolio of medical technology products organized into three main categories: Global Blood Solutions (covering blood collection, processing, pathogen reduction, and storage), Therapeutic Apheresis (providing treatment systems for conditions like sickle cell disease and therapeutic plasma exchange), and Cell Therapy Technologies (enabling scalable manufacturing for cell and gene therapies). The portfolio includes hardware systems (Trima Accel, Reveos, Spectra Optia, Quantum Flex, FINIA), software solutions (TOMEs, Cadence, Vista, Trima KPI Dashboard, EMPOWERD), and consumables. Key products like Reveos automate whole blood processing, Spectra Optia serves as the dominant apheresis platform (84% global market share), Quantum Flex enables automated cell expansion for CAR-T and other therapies, and the 3-in-1 integrated workflow automates activation, transduction, and expansion. The company also offers pathogen reduction (Mirasol), vascular access solutions, and contract manufacturing services. Terumo BCT holds 750+ granted patents with 150+ pending, operates in 160+ countries, and is a subsidiary of Terumo Corporation (TSE: 4543).
Differentiator
Problem solved
Functional benefit
Brands
- Quantum Flex: Cell Expansion System for cell therapy manufacturing
- Spectra Optia
- Reveos
- Trima Accel
- Mirasol
- FINIA
- Rika
- IMUGARD
- TOMEs
- EMPOWERD
Products and services
- Trima Accel Automated Blood Collection System Automated blood collection system for apheresis and whole blood donation collection, enabling precise component collection with integrated software for workflow management. Used by blood centers for platelet and plasma collection.
- Reveos Automated Blood Processing System FDA-cleared automated system that separates whole blood into red blood cells, plasma, and platelets in a single centrifugation cycle, improving efficiency, platelet supply, and reducing labor costs for blood centers.
- Mirasol Pathogen Reduction Technology (PRT) System Pathogen reduction technology system for treating blood products to reduce the risk of transfusion-transmitted infections. Not approved for sale in the U.S.; available in select international markets.
- Whole Blood Bag Systems Whole blood collection, component processing, and storage systems for blood centers, used as consumables alongside the company's blood processing hardware.
- Welders and Sealers Reliable, sterile connections using cost-effective tubing welders and sealers for blood processing applications.
- Spectra Optia Apheresis System Therapeutic apheresis and cell collection platform used in 84% of blood cell separation and exchange procedures globally, supporting protocols including Therapeutic Plasma Exchange, Red Blood Cell Exchange, and cell collections for hospitals and clinics.
- Quantum Flex Cell Expansion System Automated cell expansion system for scalable, repeatable manufacturing of cell therapies including CAR-T, TCR-T, Tregs, and other immune cell therapies using proprietary hollow-fiber perfusion technology, with 3-in-1 integrated workflow (activation, transduction, expansion).
- FINIA Fill and Finish System Automated fill and finish system for cell and gene therapies, enabling automated formulation, aliquoting into bags, air removal, and sealing before cryopreservation of cellular products.
- TOMEs (Terumo Operational Medical Equipment Software) Software for automating data collection and operational management for blood centers, replacing manual clipboard-based tracking with digital workflows across collection, processing, and storage operations.
- Cadence Data Collection System Data collection system for blood center operations monitoring and compliance, providing structured operational data capture.
- Vista Information System Information system for blood center management and donor/recipient tracking, supporting end-to-end visibility across blood center operations.
- Trima KPI Dashboard Data visualization and KPI tracking dashboard for Trima Accel blood collection operations, enabling performance monitoring and operational efficiency analysis.
- EMPOWERD Data Management Software Software that enhances operational efficiency and enables compliance through accurate, automated data capture and transfer from Spectra Optia apheresis systems.
- Veda Solutions Service, analytics, and consulting offerings for blood center optimization, providing operational insights and consulting engagements.
- Contract Manufacturing Services Contract manufacturing services for medical devices and blood/cell processing products, leveraging Terumo BCT's global manufacturing capabilities across eight manufacturing sites.
- IMUGARD WB Platelet Pooling Set FDA-cleared platelet pooling set enabling extended shelf life of whole blood-derived platelets from five to seven days; the first seven-day platelet storage set approved in the U.S.
- Rika Plasma Donation System Next-generation plasma collection system engineered to streamline plasma collection and improve donor experience, deployed nationwide at CSL Plasma centers across the U.S.
Quantifiable outcome
- 84% of blood cell separation and exchange procedures worldwide performed on Terumo BCT systems
- +3 more outcomes
Companies that use Terumo BCT
Customer profileNamed customers13 records
Segments5 records
Ideal customer profiles4 records
Terumo BCT technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration6 records
Feature8 records
Terumo BCT partnerships and signals
Strategic signalPartnerships
27 partnerships are on record, tiered core, strategic and regional.
- Steminent BiotherapeuticscoreStrategic collaboration to accelerate late-stage manufacturing readiness for mesenchymal stem cell (MSC) therapies. Terumo BCT leading development of scalable production workflow using Quantum Flex for clinical and commercial production of Steminent's MSC-based therapy (Stemchymal). Part of APAC C> Ecosystem Blueprint framework.
- StafaCTcoreSuccessful deployment of direct device connectivity with Terumo BCT Spectra Optia apheresis systems at leading global center for apheresis, cell therapy, and transplantation. Integration enables structured data capture directly from apheresis device, creating reliable digital foundation across clinical and operational workflows.
- Taiwan Bio TherapeuticscoreCollaboration to transition regulatory T-cell (Treg) manufacturing onto Quantum Flex automated platform. Taiwan Bio integrating Phase 2 Treg manufacturing (TregCel therapy TRK-001) with Terumo BCT's 3-in-1 workflow for cell activation, viral transduction, and expansion. Goal to reduce cost of goods sold, shorten cycle times, and support next-generation engineered Treg programs targeting IND filing.
- Liza LoidoltcoreAppointment as General Manager of Cell and Gene Therapy Business. New leadership role sharpening company's focus on accelerating innovation and access in cell and gene therapy market.
- Santersus AGcorePartnership to develop novel therapy for sepsis using Santersus' NucleoCapture blood purification technology combined with Terumo BCT's Spectra Optia Apheresis System. Includes clinical development support and Santersus leading pivotal clinical studies. Investment from Terumo Ventures.
- Hemex HealthstrategicPartnership to improve outcomes for millions with sickle cell disease and other hemoglobin disorders. Terumo BCT invests in Hemex Health, and Chetan Makam joins its Board of Directors to accelerate access to critical testing and care.
- Eliaz TherapeuticscoreFormal collaboration with Eliaz Therapeutics for apheresis technology. Eliaz developing XGal-3 apheresis device to selectively remove galectin-3 from bloodstream of sepsis patients. Company has FDA Breakthrough Device Designation and $1.9M in NIH grants.
- Kenya Ministry of HealthstrategicMoU to build coordinated national care framework for sickle cell disease. Part of Imara Sickle Cell Framework initiative to translate policy priorities into practical coordinated delivery within national health systems.
- Uganda Ministry of Health (JCRC)strategicMoU with Uganda's Joint Clinical Research Centre under stewardship of Uganda Ministry of Health for coordinated national care framework for sickle cell disease.
- Côte d'Ivoire Ministry of HealthstrategicMoU to build coordinated national care framework for sickle cell disease as part of Imara Sickle Cell Framework.
- Join ParachuteregionalJoin Parachute adopting Rika Plasma Donation System to enhance donor experience and help expand access to lifesaving therapies.
- PwC BelgiumstrategicPartnership focused on driving equitable and sustainable access to Advanced Therapy Medicinal Products (ATMPs). Breaking barriers in access to advanced cell and gene therapies.
- KBIOHealthregionalPartnership to help develop nation's cell and gene therapy workforce. KBIOHealth leveraging Terumo BCT's expertise, Quantum Flex and Finia system for advanced training programs for CGT manufacturing in Korea and beyond.
- National Alliance of Sickle Cell Centers (NASCC)strategicBET on Blood for SCD collaboration to improve lives of Sickle Cell Warriors by connecting healthcare providers with education about proven treatments to help manage the disease.
- Akron BiocoreCollaborative study on MSC expansion using Quantum Flex. Study confirms platform paired with Akron Bio's GMP virus-inactivated fibronectin reagent provides scalable and compliant solution for MSC expansion.
- Shandong Institute of Medical Devices and Pharmaceutical Packaging InspectionregionalStrategic MoU signed in Hangzhou, China to build comprehensive platform integrating industry, academia, research, and application. Aims to strengthen exchanges in medical device field, deepen academic research, promote frontier technologies, and improve professional talent skills for domestic medical health industry innovation.
- Blood Centers of AmericaregionalU.S. launch partner for Reveos Automated Blood Processing System. Used globally for over a decade in 50+ countries.
- SanquinregionalNetherlands blood bank integrating Reveos Automated Blood Processing System to enhance blood processing efficiency and increase production of essential blood products across Netherlands.
- Nova BiomedicalcoreCollaboration to bring automated cell culture sensing to Quantum Flex. Integration of Nova's BioProfile FLEX2 enables automated cell culture analyses for process development through commercial manufacturing.
- Anthony NolanregionalOpening of Anthony Nolan Cell Collection Centre in Nottingham, U.K. using Terumo BCT technology to help patients and enable cell and gene therapy research.
- Charles RivercoreDemonstration of versatility of FINIA automated fill and finish platform. New publication confirms ability to automate large volumes across multiple autologous and allogeneic cell and gene therapy workflows.
- CiRA FoundationcorePartnership to develop automated iPS cell manufacturing. Integration of Quantum Flex and expertise through collaboration. Joint research selected for AMED (Japan Agency for Medical Research and Development) funding for establishing stable and efficient expansion workflow for scalable iPS cell manufacturing.
- UK National Health Serviceregional£1.5M investment in 25 red blood cell exchange devices (Spectra Optia) to help manage sickle cell disease. Hundreds of sickle cell patients to benefit across England.
- FUJIFILM Irvine ScientificcoreCollaboration to accelerate T cell expansion for cell therapy developers. Turnkey solution using Fujifilm's PRIME-XV T Cell Expansion Media on Terumo BCT's Quantum Flex system to simplify and scale T cell expansion for developers.
- 908 DevicescoreCollaboration to add on-line analytics to Quantum Flex Cell Expansion System. Automation combined with on-line monitoring during cell expansion brings manufacturing efficiencies and enables increased patient accessibility and safety.
- BioCentriqcoreStudy to generate public CAR-T cell data using Terumo BCT's CGT manufacturing platforms. Data detailing Quantum Flex and Finia systems with BioCentriq's LEAP Advanced Therapy Platform to help accelerate delivery of CAR-T therapies.
- MCQcoreCollaboration to enable automated gas mixing for expansion of cell and gene therapies. Pairing of MCQ Nano 3 enables custom gas mixing for Quantum Flex Cell Expansion System.
Scale indicators9 records
Recent moves9 records
Expansion highlights8 records
Terumo BCT competitors and assessment
Company assessmentDirect peers
- Haemonetics Corporation: Haemonetics is a direct competitor in blood and plasma component collection, offering apheresis and whole blood processing systems that overlap directly with Terumo BCT's Spectra Optia and Reveos product lines for blood centers and hospitals globally.
- Fresenius Kabi: Fresenius Kabi competes directly in blood collection, apheresis, and transfusion medicine through its COM.TEC and Alyx product families, sharing Terumo BCT's enterprise blood center and hospital customer base worldwide.
- Miltenyi Biotec: Miltenyi Biotec's Prodigy platform competes directly with Terumo BCT's Quantum Flex cell expansion system in the cell therapy manufacturing market, targeting the same CAR-T and cell therapy developer customers with automated bioreactor and processing solutions.
- Cerus Corporation: Cerus competes directly with Terumo BCT's Mirasol Pathogen Reduction Technology through its INTERCEPT blood system, serving the same blood center customers for pathogen reduction in platelets and plasma.
- Macopharma: Macopharma is a direct peer in blood bag systems, sterile tubing welders, and pathogen reduction technologies, competing with Terumo BCT's whole blood bag systems and related blood center consumables portfolio.
Broad incumbents
- Grifols: Grifols is a broader blood products incumbent operating plasma collection centers, fractionation, and blood-typing diagnostics, with overlapping infrastructure in the plasma collection value chain where Terumo BCT's Rika system is deployed.
- Lonza Group: Lonza is a leading cell and gene therapy CDMO with the Cocoon platform, competing with Terumo BCT's Quantum Flex for commercial cell therapy manufacturing relationships and serving similar biotech developer customers.
- Cytiva: Cytiva (formerly GE Healthcare Life Sciences) offers Xuri cell expansion systems and bioprocessing infrastructure that compete with Terumo BCT's cell therapy portfolio while also serving broader biomanufacturing customers.
- Sartorius AG: Sartorius is a bioprocessing incumbent offering cell and gene therapy manufacturing platforms, bioreactors, and downstream processing that overlap with Terumo BCT's cell therapy technology business at biotech and pharma customers.
Regional players
- Asahi Kasei Medical: Asahi Kasei Medical, part of Japanese conglomerate Asahi Kasei, offers blood purification and apheresis technologies primarily in APAC markets, making it a regional peer to Terumo BCT with comparable product categories in transfusion medicine and cell therapy.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat7 records
Key risks6 records
Key highlights7 records
Customer concentration
Terumo BCT social profiles
Digital presenceTerumo BCT financial estimates
Financial estimateRevenue estimate
Valuation estimate
Terumo BCT leadership team
Management profileNumber of profiles
Profiles12 records
Terumo BCT funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Terumo BCT M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Terumo BCT
What does Terumo BCT do?
Terumo BCT develops, manufactures, and services medical technology products for the collection, processing, and delivery of blood and cell-based therapies. The portfolio spans automated blood collection and processing systems (Trima Accel, Reveos), therapeutic apheresis platforms (Spectra Optia), cell therapy manufacturing systems (Quantum Flex, FINIA), pathogen reduction technology (Mirasol), plasma collection systems (Rika), and supporting consumables and data management software.
Is Terumo BCT a public or private company?
Terumo BCT is a private company. It is classified as corporate owned and is currently operating.
When was Terumo BCT founded?
Terumo BCT was founded in 1964. It employs 5,001 to 10,000 people.
Where is Terumo BCT based?
Terumo BCT is headquartered in Lakewood, United States, in the North America region.
How does Terumo BCT make money?
Three revenue lines are on record. Medical Device Hardware Sales are the primary driver. The others are software and Services and contract Manufacturing.
Who are Terumo BCT's main competitors?
Direct peers on record are Haemonetics Corporation, Fresenius Kabi, Miltenyi Biotec, Cerus Corporation and Macopharma. Broad incumbents are Grifols, Lonza Group, Cytiva and Sartorius AG. Asahi Kasei Medical is listed as a regional player.
Does Terumo BCT have an API?
No public API is recorded for Terumo BCT.
What industry is Terumo BCT in?
Terumo BCT's product category is Blood and Cell Processing Medical Devices. Its primary akta.pro industry code is HLAGABAD, Cell Therapy CDMO, with a secondary code of HLAAACAN, Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream). Its NAICS code is 339112 and its SIC code is 3841.